June 9, 2009Catheterization and Cardiovascular Interventions
Antiplatelet therapy discontinuation following drug‐eluting stent placement: Dangers, reasons, and management recommendations
Key result
Premature discontinuation of dual antiplatelet therapy after drug-eluting stent placement markedly increases the risk of late stent thrombosis, which has a baseline incidence of 0.4-0.6%/year.
Why the study?
Does premature discontinuation of dual antiplatelet therapy increase the risk of stent thrombosis in patients following drug-eluting stent placement?
Population
Patients following drug-eluting stent (DES) placement
Comparison
Dual antiplatelet therapy with aspirin and… vs Premature DAT discontinuation
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Clinicians should counsel against premature DAPT discontinuation post-DES; review supports association but leaves optimal duration open.
Structured PICO
Does premature discontinuation of dual antiplatelet therapy increase the risk of stent thrombosis in patients following drug-eluting stent placement?
P
Population
Patients following drug-eluting stent (DES) placement
I
Intervention
Dual antiplatelet therapy (DAT) with aspirin and clopidogrel for ≥ 12 months
C
Comparator
Premature DAT discontinuation
O
Outcome
Late stent thrombosis (ST)hard clinical
Premature discontinuation of dual antiplatelet therapy after drug-eluting stent placement significantly increases the risk of catastrophic late stent thrombosis, highlighting the need for patient education and adherence.
Cite This Study
Moussa et al. (2009) conducted a review in Drug-eluting stent placement. Dual antiplatelet therapy (DAT) was evaluated on Late stent thrombosis. Premature discontinuation of dual antiplatelet therapy after drug-eluting stent placement markedly increases the risk of late stent thrombosis, which has a baseline incidence of 0.4-0.6%/year.